Polydiuretic Therapy for Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus
Status:
Recruiting
Trial end date:
2022-03-30
Target enrollment:
Participant gender:
Summary
This is a single-center, non-randomzied pilot study investigating a combination of targeted
therapies as possible treatment for heart failure with preserved ejection fraction (HFpEF).
The study interviention is a Low-Dose, Triple Polydiuretic Therapy (LDTPT, or polydiuretic)
including loop diuretic (bumetanide), mineralocorticoid receptor antagonist (eplerenone), and
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) therapy (dapaglifozin).